December 20, 2009, Updated September 24, 2012

Jerusalem-based stem cell therapy start-up Gamida Cell has launched a feasibility study to evaluate the preclinical (animal study) safety and efficacy of a gene therapy product which may have potential to treat congenital anemias such as Cooley’s Anemia.

The product combines technology from both Weill Cornell Medical College and Gamida Cell. Weill Cornell is seeking to develop a cure for beta-thalassemia, generally known as Cooley’s anemia, and sickle cell anemia, the most common inherited anemias.

Gamida Cell’s lead product, StemEx, based on adult stem cells derived from umbilical cord blood, is used today as an experimental treatment for blood cancers such as leukemia and lymphoma. StemEx has been granted orphan drug status in the US and Europe.

Gamida Cell’s investors include Teva, Elbit Imaging, Biomedical Investment, Israel Healthcare Ventures, Amgen, Denali Ventures and Auriga Ventures.

Fighting for Israel's truth

We cover what makes life in Israel so special — it's people. A non-profit organization, ISRAEL21c's team of journalists are committed to telling stories that humanize Israelis and show their positive impact on our world. You can bring these stories to life by making a donation of $6/month. 

Jason Harris

Jason Harris

Executive Director

Read more: